Tuberculosis Clinical Trials 2023

Tuberculosis Clinical Trials 2023

Tuberculosis research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in tuberculosis clinical trials today.

Trials for LTBI Patients

Trials for TB Patients

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to tuberculosis

What are the top hospitals conducting tuberculosis research?

In the ongoing battle against tuberculosis, several hospitals are leading the charge in clinical trials. One such site is located in Lincoln, where researchers are currently conducting a singular active trial focused on tuberculosis. This hospital has recorded one trial overall since its first investigation into this condition in 2023. Similarly, Denver Health and Hospitals at TBTC Site 22 in Denver also have one ongoing tuberculosis trial with a single trial completed to date, starting their research journey alongside Lincoln's facility as well.

Moving east to Brooklyn, TBTC Site 64 at the Brooklyn Campus of VA NY Harbor Healthcare System joins the ranks with one active tuberculosis trial and an all-time count of one conducted investigation. Simultaneously within Jackson Heights lies another dedicated center for combating tuberculosis; The New york City Department of Health and Mental Hygiene- Corona Chest Center (TBTC Site 64A), they too share similar statistics regarding their pursuit focusing solely on current solitary test while joining other facilities commencing investigations related to Tuberculosis around same time frame from year 2023 onwards.

Lastly but equally noteworthy is TBTC Site 63 situated at San Antonio VA Medical Center encapsulating an additional perspective on sustained efforts addressing tuberculosis issue not only through existing sole active clinical exploration but by contributing two earlier held trials as well; thus implying longer experience dating back till2016.

Although these hospitals may have fewer active trials for tuberculosis compared to other diseases or conditions, every step forward matters greatly in unraveling new treatment options and potential cures for this highly infectious disease that continues to impact populations worldwide. Together, these institutions exemplify unwavering commitment towards conquering tuberculosis through scientific innovation and compassion-driven healthcare practices

Which are the best cities for tuberculosis clinical trials?

Among the cities leading tuberculosis clinical trials, San Antonio, Texas shows promise with 3 active studies exploring treatments such as Rifapentine daily for 6 weeks and 2BMZRb/2 BMRb. Seattle, Washington also stands out with its research on interventions like BCG Challenged-Isoniazid Treated and Rifapentine daily for 6 weeks through their 3 ongoing trials. Additionally, Denver, Colorado conducts two active trials investigating approaches like 2BMZRb/2 BMRb and Rifapentine daily for 6 weeks. While Baltimore, Maryland and Nashville, Tennessee each have two active trials focusing on alternative strategies including Video Directly Observed Therapy plus Financial Incentives and BCG (Tokyo 172) vaccine respectively. These cities contribute to advancing tuberculosis care through their commitment to clinical research.

Which are the top treatments for tuberculosis being explored in clinical trials?

In the realm of tuberculosis treatment, a couple of innovative approaches are taking center stage in ongoing clinical trials. MK-7762 (TBD09) has shown promise and is currently being explored in one active trial, marking its debut on the scene in 2023. Another intriguing contender is Video Directly Observed Therapy plus Financial Incentives, which combines technology and incentives to enhance treatment adherence. It too is undergoing evaluation through one active trial since its introduction in 2022. As researchers delve deeper into these novel treatments, hopes rise for more effective strategies against tuberculosis.

What are the most recent clinical trials for tuberculosis?

Recent clinical trials offer hope in the battle against tuberculosis. One such trial investigates the efficacy of 2BMZRb/2 BMRb, a potential treatment for tuberculosis that has reached Phase 3. In another study, MK-7762 (TBD09) is being evaluated in Phase 1 as a possible therapy option. Additionally, researchers are exploring BCG Challenged-Isoniazid Treated and its effects on tuberculosis through a Phase 1 trial. These trials highlight ongoing efforts to combat this disease and bring us closer to improved treatments for patients worldwide.

What tuberculosis clinical trials were recently completed?

In October 2020, the National Institute of Allergy and Infectious Diseases (NIAID) successfully completed a clinical trial investigating the potential of Imatinib in treating tuberculosis. This trial marks an important step in advancing our understanding and treatment options for this persistent infectious disease. Through rigorous research efforts like these, we strive to develop more effective therapies that can make a significant impact on global tuberculosis control.